Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

The company is best known for its drug, Ingrezza. Ingrezza treats tardive dyskinesia and chorea associated with Huntington's disease. Both are movement disorders. But in the fourth quarter ...